Literature DB >> 28469294

What's inside.

Arabind Panda1.   

Abstract

Entities:  

Year:  2017        PMID: 28469294      PMCID: PMC5396415          DOI: 10.4103/iju.IJU_96_17

Source DB:  PubMed          Journal:  Indian J Urol        ISSN: 0970-1591


× No keyword cloud information.

MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING: TRANSRECTAL ULTRASOUND-GUIDED FUSION BIOPSY

Prostate cancer in India presents late and remains an important cause of death in men. Bansal et al.[1] present data regarding the use of multiparametric-magnetic resonance imaging transrectal ultrasound fusion biopsy in an Indian cohort of patients. Prostate cancer in India may have a different presentation compared to the West, and Indian data can help us further refine our management protocols.

PENILE URETHRAL STRICTURES

Strictures of the penile urethra are difficult to manage. Skin flaps to grafts have all been used with varying degrees of success. Joshi et al.[2] present a composite two-stage urethroplasty for complex penile strictures without balanitis xerotica obliterans (BXO). The buccal mucosal graft (BMG) was applied in the second stage and immediately tubularized. This is distinct from the commonly performed technique of applying the BMG in the first stage. Despite excluding BXO strictures, the patients included both failed hypospadias repair and other causes of urethral strictures. Residual chordee in the former group will present a challenge, but the concept that immediate tubularization will aid take of the graft due to a moist environment has merit and can improve results.

PROGNOSTICATING AND NOVEL THERAPY FOR BLADDER CANCER: THE ROLE OF MICRO-RNAS

Recurrent bladder cancer is hypothesized to be a result of field change in the transitional epithelium of the urinary tract. Markers for progression and invasiveness can help us offer management options that are tailored to the individual patient. Mitash et al.[3] review the role of cellular metabolic regulatory molecules, such as micro-RNA, which can be used as biomarkers to prognosticate or as targeted therapy for bladder cancer.

AN INCONTINENCE ACTIVITY PARTICIPATION SCALE FOR SPINAL CORD INJURY

Walia and Kaur[4] present a novel scale to measure the involvement of spinal cord injured (SCI) patients in life situations. Incontinence is a major barrier for increased participation in activities outside their homes. The scale should help urologists quantify the problems of SCI patients and follow up on the success of therapy.

EXTENDED – SPECTRUM BETA-LACTAMASE – PRODUCING, CARBAPENEM-RESISTANT UROPATHOGENS MAY BE FOSFOMYCIN SENSITIVE

Carbapenem-resistant pathogens have rapidly spread to almost all hospital settings. They remain perhaps the greatest threat to our attempts to control serious nosocomial infections. Banerjee et al.[5] discuss the role of fosfomycin in the treatment of such isolates. However, the translation of in vitro sensitivity into in vivo success and clinical usefulness of this drug remains to be seen.

DOES THE INDICATION FOR PARTIAL NEPHRECTOMY AFFECT THE COMPLICATION AND OUTCOMES?

Venkatramani et al.[6] reviewed data to see if the preoperative indications for partial nephrectomy (elective, relative, and absolute) affected the perioperative complications and outcome. The results point to fewer complications in the elective arm.

CAN STERILE WATER IRRIGATION BE A SUBSTITUTE FOR SINGLE-DOSE MITOMYCIN-C AFTER TRANSURETHRAL RESECTION OF BLADDER TUMORS?

The use of intravesical mitomycin-C immediately after transurethral resection of bladder tumor is common in an attempt to prevent tumor cell re-implantation and consequent recurrence. In a randomized controlled trial, Bijalwan et al.[7] compared continuous irrigation with sterile water to a single intravesical mitomycin C instillation and detected no significant difference.

BLADDER CANCER: WHAT THE FUTURE HOLDS?

While radical cystectomy remains the primary surgery for muscle invasive bladder cancer, the therapy is multimodal. The treatment of advanced bladder cancer has changed over the years with newer chemotherapeutic agents and molecular subtyping of the cancer. This issue has a symposium on muscle invasive bladder cancer guest edited by Kamat[8] which discusses the newer trends in therapy.

SURGICAL MANAGEMENT OF MUSCLE INVASIVE BLADDER CANCER

Treatment of muscle invasive bladder cancer continues to evolve with ongoing discussions on the use of neoadjuvant chemotherapy, extent of pelvic lymph node dissection, and an attempt on organ preservation. Kukreja and Shah[9] discuss the advances in its surgical management.

BLADDER PRESERVATION IN SELECTED CASES OF MUSCLE INVASIVE CANCER

Radical cystectomy is the gold standard for muscle invasive bladder cancer. Wade-Smelser et al.[10] review the role of bladder preservation in selected cases, indications, and oncological outcomes. The quality of life after such therapy is also discussed.

SYSTEMIC THERAPY IN BLADDER CANCER

Neoadjuvant therapy for muscle invasive disease has achieved better survival rates than primary surgery. All patients who may benefit from therapy, however, do not receive it. Pinto[11] discusses the agents used in neoadjuvant and adjuvant settings in muscle invasive disease. The role of second-line immunotherapy is also discussed.
  11 in total

1.  Bladder cancer: 2017 and beyond.

Authors:  Ashish M Kamat
Journal:  Indian J Urol       Date:  2017 Apr-Jun

2.  Perioperative complications and postoperative outcomes of partial nephrectomy for renal cell carcinoma: Does indication matter?

Authors:  Vivek Venkatramani; Santosh Kumar; J Chandrasingh; Antony Devasia; Nitin S Kekre
Journal:  Indian J Urol       Date:  2017 Apr-Jun

Review 3.  Advances in surgical management of muscle invasive bladder cancer.

Authors:  Janet Baack Kukreja; Jay B Shah
Journal:  Indian J Urol       Date:  2017 Apr-Jun

Review 4.  Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?

Authors:  Woodson Wade Smelser; Marcus A Austenfeld; Jeffrey Maxwell Holzbeierlein; Eugene Kang Lee
Journal:  Indian J Urol       Date:  2017 Apr-Jun

5.  Comparison of sterile water irrigation versus intravesical mitomycin C in preventing recurrence of nonmuscle invasive bladder cancer after transurethral resection.

Authors:  Priyank Bijalwan; Ginil Kumar Pooleri; Appu Thomas
Journal:  Indian J Urol       Date:  2017 Apr-Jun

Review 6.  Bladder cancer: Micro RNAs as biomolecules for prognostication and surveillance.

Authors:  Nilay Mitash; Swasti Tiwari; Shalini Agnihotri; Anil Mandhani
Journal:  Indian J Urol       Date:  2017 Apr-Jun

7.  A novel composite two-stage urethroplasty for complex penile strictures: A multicenter experience.

Authors:  Pankaj M Joshi; Guido Barbagli; Vikram Batra; Sandesh Surana; Atef Hamouda; Salvatore Sansalone; Dimitris Costi; Massimo Lazzeri; Craig Hunter; Devang J Desai; Fabio Castiglione; Sanjay B Kulkarni
Journal:  Indian J Urol       Date:  2017 Apr-Jun

Review 8.  Systemic therapy in bladder cancer.

Authors:  Ian G Pinto
Journal:  Indian J Urol       Date:  2017 Apr-Jun

9.  Multiparametric magnetic resonance imaging-transrectal ultrasound fusion prostate biopsy: A prospective, single centre study.

Authors:  Somendra Bansal; Narmada P Gupta; Rajiv Yadav; Rakesh Khera; Kulbir Ahlawat; Dheeraj Gautam; Rajesh Ahlawat; Gagan Gautam
Journal:  Indian J Urol       Date:  2017 Apr-Jun

10.  Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens.

Authors:  Sayantan Banerjee; Mallika Sengupta; Tanoy Kumer Sarker
Journal:  Indian J Urol       Date:  2017 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.